Introduction
Leading pharmaceutical company’s antibiotic Zaynich received favourable recommendation from CDSCO’s Subject Expert Committee for treating Gram-negative infections, advancing regulatory approval in India.
Share price movement of Wockhardt
On March 30, 2026, Wockhardt Ltd opened at ₹1,185.00, down 0.34% from its previous close of ₹1,189.05. The stock reached a high of ₹1,231.30 (3.57%) and a low of ₹1,173.05. By 3:15 PM, it traded at ₹1,178.20, a 0.91% decrease, with a market cap of ₹19,144.05 crore.
Wockhardt’s Zaynich® Gets CDSCO Nod
Wockhardt Limited’s antibiotic, Zaynich® (Zidebactam/Cefepime), received a favourable recommendation from CDSCO’s Subject Expert Committee for marketing approval. The recommendation covers treatment of Gram-negative infections in India.
The approval follows review of non-clinical data, nine Phase 1 studies, a global Phase 3 study in cUTI/AP, a Phase 2 study in meropenem-resistant infections, and 85 compassionate-use cases.
Zaynich® was developed over 15 years by 150+ scientists. It demonstrated high clinical efficacy in real-world studies and compassionate-use cases, addressing multidrug-resistant and extensively drug-resistant Gram-negative infections globally.
Stock performance of Wockhardt for period of 1 week, 6 months, and 1 year
Wockhardt Ltd delivered a 1-week return of 8.11%, a 6-month return of -20.3%, and a 1-year return of -16.5%.
Also Read: Ceinsys Tech shares jump after securing multi-year ISRO deal worth ₹3.24 Cr
Shareholding pattern of Wockhardt
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 49.10% | 49.10% | 49.10% |
| FII | 7.00% | 7.10% | 7.30% |
| DII | 10.60% | 11.00% | 11.00% |
| Public | 33.40% | 32.80% | 32.60% |
About Wockhardt
Wockhardt Ltd (NSE: WOCKPHARMA) is a global pharmaceutical and biotechnology company manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topical products including creams and ointments.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Wockhardt Ltd share price rising today?
A: Wockhardt Ltd share price gained after Zaynich® (Zidebactam/Cefepime) received favourable recommendation from CDSCO’s Subject Expert Committee for Gram-negative infections.
Q: What is Wockhardt Ltd’s main business focus?
A: Wockhardt Ltd focuses on pharmaceuticals and biotechnology, manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topical products globally.
Q: What are the 52-week high and low of Wockhardt Ltd stock?
A: The 52-week high of Wockhardt Ltd is ₹1,870.00, and the low is ₹1,086.80.
